Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA A Cancer J Clin. 2024;74:12–49. https://doi.org/10.3322/caac.21820.

Article  Google Scholar 

Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiówka M, Hewson N, et al. Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study. J Clin Oncol. 2015;33:3781–7. https://doi.org/10.1200/JCO.2015.61.5831.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robertson JFR, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27:4530–5. https://doi.org/10.1200/JCO.2008.21.1136.

Article  CAS  PubMed  Google Scholar 

Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388:2997–3005. https://doi.org/10.1016/S0140-6736(16)32389-3.

Article  CAS  PubMed  Google Scholar 

FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. In: FDA [Internet]. FDA; 27 Jan 2023 [cited 21 Jun 2024]. Available: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer

Clusan L, Ferrière F, Flouriot G, Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int J Mol Sci. 2023;24:6834. https://doi.org/10.3390/ijms24076834.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brufsky AM, Dickler MN. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. Oncologist. 2018;23:528–39. https://doi.org/10.1634/theoncologist.2017-0423.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paterni I, Granchi C, Katzenellenbogen JA, Minutolo F. Estrogen Receptors Alpha (ERα) and Beta (ERβ): Subtype-Selective Ligands and Clinical Potential. Steroids. 2014;90:13–29. https://doi.org/10.1016/j.steroids.2014.06.012.

Article  CAS  PubMed  Google Scholar 

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84.

Article  Google Scholar 

Burstein HJ. Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. N Engl J Med. 2020;383:2557–70. https://doi.org/10.1056/NEJMra1307118.

Article  CAS  PubMed  Google Scholar 

Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321:288–300. https://doi.org/10.1001/jama.2018.19323.

Article  CAS  PubMed  Google Scholar 

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017;377:1836–46. https://doi.org/10.1056/NEJMoa1701830.

Article  PubMed  PubMed Central  Google Scholar 

Shiino S, Kinoshita T, Yoshida M, Jimbo K, Asaga S, Takayama S, et al. Prognostic Impact of Discordance in Hormone Receptor Status Between Primary and Recurrent Sites in Patients With Recurrent Breast Cancer. Clin Breast Cancer. 2016;16:e133-140. https://doi.org/10.1016/j.clbc.2016.05.014.

Article  CAS  PubMed  Google Scholar 

Gnant M, Turner NC, Hernando C. Managing a Long and Winding Road: Estrogen Receptor-Positive Breast Cancer. Am Soc Clin Oncol Educ Book. 2023;43:e390922. https://doi.org/10.1200/EDBK_390922.

Article  PubMed  Google Scholar 

Reinert T, Saad ED, Barrios CH, Bines J. Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer. Front Oncol. 2017;7:26. https://doi.org/10.3389/fonc.2017.00026.

Article  PubMed  PubMed Central  Google Scholar 

Malorni L, Piazza S, Ciani Y, Guarducci C, Bonechi M, Biagioni C, et al. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget. 2016;7:68012–22.

Article  PubMed  PubMed Central  Google Scholar 

Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020;38:3987–98. https://doi.org/10.1200/JCO.20.02514.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35:3638–46. https://doi.org/10.1200/JCO.2017.75.6155.

Article  CAS  PubMed  Google Scholar 

Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im S-A, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465–72. https://doi.org/10.1200/JCO.2018.78.9909.

Article  CAS  PubMed  Google Scholar 

Tripathy D, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904–15. https://doi.org/10.1016/S1470-2045(18)30292-4.

Article  CAS  PubMed  Google Scholar 

Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35. https://doi.org/10.1016/S1470-2045(14)71159-3.

Article  CAS  PubMed  Google Scholar 

Cristofanilli M, Rugo HS, Im S-A, Slamon DJ, Harbeck N, Bondarenko I, et al. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clin Cancer Res. 2022;28:3433–42. https://doi.org/10.1158/1078-0432.CCR-22-0305.

Article  CAS  PubMed  PubMed Central  Google Scholar 

André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380:1929–40. https://doi.org/10.1056/NEJMoa1813904.

Article  PubMed  Google Scholar 

Jhaveri K, Im S-A, Saura C, Juric D, Loibl S, Kalinsky K, et al. GS03–13: Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis. San Antonio Breast Cancer Symposium 2023; 2023 Dec 8; San Antonio, TX. Available: https://aacr.ent.box.com/s/im3djx6fp13rad4kr3fmaf5ijj251pni

Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388:2058–70. https://doi.org/10.1056/NEJMoa2214131.

Article  CAS  PubMed  Google Scholar 

Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, et al. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. J Clin Oncol. 2018;36:1556. https://doi.org/10.1200/JCO.2017.76.9331.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2012;366:520–9. https://doi.org/10.1056/NEJMoa1109653.

Article  CAS  PubMed  Google Scholar 

Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;90(Suppl 1):S2-6. https://doi.org/10.1038/sj.bjc.6601629.

Article  CAS  PubMed  PubMed Central